Gore’s Cardioform ASD Occluder Evaluated at 3 Years in ASSURED Trial
September 30, 2024—Gore & Associates announced the release of 3-year data from the ASSURED clinical study, which is evaluating the long-term safety and efficacy of treating ostium secundum atrial septal defects (ASDs) with the company’s Cardioform ASD occluder.
